Research Article
Impact of Body Mass Index on Short-Term Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Newfoundland and Labrador, Canada
Table 5
Multivariate adjusted OR for vascular complications in patients undergoing PCI.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adjusted for access site, age, aspirin, BMI, closure device, diabetes, gender, GI/liver disease, LMWH in-lab, preprocedural LMWH, GP IIb/IIIa inhibitors in-lab, preprocedural GP IIb/IIIa inhibitors, preprocedural IV heparin, prior CVD, prior HF, prior PCI, sheath size, smoking status, ticlopidine/clopidogrel, and year. BMI: body mass index; CVD: cardiovascular disease; GP: glycoprotein; HF: heart failure; LMWH: low molecular weight heparin; PCI: percutaneous coronary intervention. |